Cited by 454Epigenetics and DNA MethylationGenomics and Chromatin DynamicsGenetics and Neurodevelopmental Disorders

Epigenetic mechanisms in neurological disease

Open access
Jakovcevski, Mira, Akbarian, Schahram·2012·Nature Medicine

Abstract

The exploration of brain epigenomes, which consist of various types of DNA methylation and covalent histone modifications, is providing new and unprecedented insights into the mechanisms of neural development, neurological disease and aging. Traditionally, chromatin defects in the brain were considered static lesions of early development that occurred in the context of rare genetic syndromes, but it is now clear that mutations and maladaptations of the epigenetic machinery cover a much wider continuum that includes adult-onset neurodegenerative disease. Here, we describe how recent advances in neuroepigenetics have contributed to an improved mechanistic understanding of developmental and degenerative brain disorders, and we discuss how they could influence the development of future therapies for these conditions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.2828

Cites

155 of 155 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several neurological disorders, including Rhett Syndrome, Smith-Magenis syndrome and schizophrenia, are characterized by dysregulation of L1 activity.

    “several neurological disorders, including Rhett Syndrome, Smith–Magenis syndrome and schizophrenia are characterized by dysregulation of L1 activity27,45,47.”

    From SIRT6 represses LINE1 retrotransposons by ribosylating KAP1 but this repression fails with stress and age (2014) · cites this paper as [47]

    In “Mutations affecting DNA methylation and neurological disease” (page unavailable), the review links Rett syndrome to MeCP2 defects and reports de-repression of retrotransposons in MeCP2-deficient neuronal chromatin. It does not establish dysregulated L1 activity as a characteristic of Smith–Magenis syndrome or schizophrenia; its mention of schizophrenia concerns MECP2 variants, not L1 activity. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Monogenetic brain disorders exist in which the phenotype is driven by mutations in genes encoding epigenetic modifiers, such as Rett Syndrome.

    “For example, there are monogenetic brain disorders in which the phenotype is driven by mutations in genes encoding epigenetic modifiers, such as Rett Syndrome (see ref 38 for review).”

    From Epigenetics and depression (2019) · cites this paper as [38]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jakovcevski, M., & Akbarian, S.
Affiliations
University of Massachusetts Chan Medical School (US)
Corresponding author
Akbarian, Schahram
Venue
Nature Medicine
Published
2012-08
Volume
18
Issue
8
Pages
1194-1204
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2012089320
Cited by
450
References
155
Citations by year
2026: 18 · 2025: 20 · 2024: 25 · 2023: 16 · 2022: 26 · 2021: 18 · 2020: 27 · 2019: 28 · 2018: 33 · 2017: 57 · 2016: 44 · 2015: 48 · 2014: 48 · 2013: 34 · 2012: 5
FWCI
3.98
Type
journal article
Language
en
Open access
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Autism Speaks
  • National Institutes of Health
  • Defense Advanced Research Projects Agency
  • National Institute of Mental Health (P50MH096890, R01MH086509, R01MH093332)
  • National Institute on Drug Abuse
  • National Institute of Neurological Disorders and Stroke (R21NS076958)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
neuroepigenetics, epigenetic mechanisms, neurodevelopmental disorders, neurodegenerative diseases, DNA methylation, histone modifications, chromatin, epigenetic therapy, aging, adult-onset neurodegeneration
MeSH terms
Animals, Chromatin, Histones, Humans, Nervous System Diseases, DNA Methylation, Epigenesis, Genetic, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review